Bounded Senolytic signal: Objective response was observed in 9 (21%) patients, including 2 complete responses (CR), 3 CRi, and 4 morphologic leuke

Selected angle: source

One-sentence thesis

The direct receipts support a narrow working claim: Objective response was observed in 9 (21%) patients, including 2 complete responses (CR), 3 CRi, and 4 morphologic leukemia‐free state (MLFS); Responses were observed in 4 (50%) of 8 RUNX1‐mutated patients. The context receipts provide source breadth and boundary checks, not independent confirmation of the lead claim.

Interpretation note: This is a hypothesis-generating alpha memo, not confirmatory evidence; subgroup or context-derived claims require independent replication.

Why this is surprising

Real tension: the useful signal is narrower than the topic label. The lead receipts support the core claim, while the added A/B context receipts define where that claim may generalize, fail, or need a separate extraction.

Evidence receipts

• fact_id=158216 (A_core) — Objective response was observed in 9 (21%) patients, including 2 complete responses (CR), 3 CRi, and 4 morphologic leukemia‐free state (MLFS). doi=10.1002/ajh.25000
• fact_id=158219 (A_core) — Responses were observed in 4 (50%) of 8 RUNX1‐mutated patients. doi=10.1002/ajh.25000
• fact_id=146494 (A_core) — event-free survival is 74.6% doi=10.1200/jco.23.01075
• fact_id=146493 (A_core) — disease-free survival is 75.8% doi=10.1200/jco.23.01075
• fact_id=173069 (A_core) — The CR/CRi rates of 50% (22 of 44 patients) were superior to 23% in a matched AML cohort treated with HMA alone (P = .005). doi=10.1002/ajh.25978
• fact_id=151096 (A_core) — 67% of patients (all doses) achieved complete remission (CR) + CR with incomplete count recovery (CRi) doi=10.1182/blood-2018-08-868752
• fact_id=173071 (A_core) — A group of 14 patients (33.3%) attained CR/CRi doi=10.1002/ajh.25978
• fact_id=169371 (A_core) — The overall response rate (CR+CRh+CRp+CRi+PR+MLFS) was 88% (23/26 pts). doi=10.1182/blood-2024-204375

Context receipts

Boundary evidence only; these receipts broaden source context but do not independently prove the lead claim.

• fact_id=158217 (B_context) — Median survival was 3.0 months (range, 0.5–8.0) doi=10.1002/ajh.25000
• fact_id=90736 (B_context) — Significant increases in epigenetic age acceleration were observed in first-generation epigenetic clocks and mitotic clocks at 3 and 6 months doi=10.18632/aging.205581

What this changes

Treat this as a focused working signal, not a broad topic claim. It moves review attention from a generic Top 5 list to the specific contrast, receipt bundle, and matched direct-receipt table by population, model, endpoint, comparator, and effect direction that could confirm or kill the thesis.

Limitations

• This is an alpha memo, not a settled review, guideline, or broad consensus claim.
• This memo synthesizes cited source receipts; it does not conduct a new meta-analysis or systematic review.
• Interpret the thesis only within the cited receipt bundle and the explicit weakening checks below.
• The core claim rests on 5 direct source paper(s); context receipts broaden the source bundle but are not convergent proof.
• Independent receipts fail to reproduce the claimed contrast.
• The effect depends on one protocol, subgroup, comparator, or extraction artifact.

What would weaken this

• Independent receipts fail to reproduce the claimed contrast.
• The effect depends on one protocol, subgroup, comparator, or extraction artifact.

Strongest counter-evidence

• fact_id=157860 (A_core) — Seven R/R AML pts received ENA + AZA + VEN triplet, and with median follow up of 11.2 mo, median OS was not reached and 6-mo OS was 70%. Source: Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for inte
• fact_id=164159 (A_core) — related mortality was not increased (2%) Source: A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma
• fact_id=151018 (B_context) — the maximal cytostatic doses for D and/or Q (1 + 1 μM) lacked efficacy in removing doxorubicin-induced β-gal-positive senescent cells Source: Senolytic Cocktail Dasatinib+Quercetin (D+Q) Does Not Enhance the Efficacy of Senescence-Inducing Chemotherapy in Liver Cancer

Next extraction

• Extract independent A_core/B_context receipts that test the lead contrast directly.
• Audit whether each direct receipt remains comparable on population, endpoint, comparator, and measurement method.
• Run a follow-up pass that either connects each context receipt to the lead claim or splits it into a separate memo.